Acorda Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Acorda Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Acorda Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Acorda Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Product Categories
Overview
- Is an extended-release oral dalfampridine formulation. - Holds the FDA approval as an oral drug administered for improving walking in people with MS. - Acorda commercializes Ampyra through an agreement with Biogen International GmbH (Biogen) outside the US under the brand name, Fampyra. Fampyra is approved in various countries including Europe, Asia, and the Americas (excluding the US).
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
- Is the only inhaled levodopa (L-dopa) which holds the FDA approval for the intermittent treatment of OFF episodes in people with Parkinson’s disease and on a carbidopa or L-dopa regimen. - It uses the company’s ArCUS platform for inhaled therapeutics - Acorda’s Inbrija received the European Commission Marketing Authorization Application (MAA) as an intermittent treatment for episodic motor fluctuations or OFF episodes in adult patients with Parkinson’s disease and who were previously treated with a dopa-decarboxylase inhibitor or levodopa. The MAA approval also enables the company to market Inbrija in 27 countries in the European Union (EU), Iceland, Liechtenstein, and Norway. - The company sells Inbrija in the US through its own sales force, a network of specialty pharmacies, and through ASD Specialty Healthcare Inc, an affiliate of AmeriSource Bergen.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer